What are the key takeaways from this Beyond Biotech episode?

Key insights include: **Nonsense mutation universe:** Only approximately 19 nonsense mutations exist in nature, making them a contained, tractable target class. AP-003 focuses on ARG2TGA, the most prevalent of these 19 stop signals. Because these mutations are conserved across different genes and diseases, one engineered tRNA can address multiple conditions rather than requiring disease-by-disease drug development programs.; **tRNA mechanism — readthrough restoration:** AP-003 works by recognizing a premature stop codon, retrieving the correct amino acid, and inserting it into the growing protein chain to restore full-length functional protein. Preclinical animal models demonstrate not just protein restoration but downstream biomarker changes confirming that restored protein is biologically functional, not merely present.; **Basket trial design for rare disease recruitment:** Grouping multiple inborn errors of metabolism sharing the ARG2TGA mutation into one trial solves a core rare disease problem — insufficient patient numbers per indication. Combining seven to ten diseases with shared inclusion/exclusion criteria and overlapping efficacy endpoints compresses recruitment timelines from potentially years per disease to a single concurrent study.

What did Trna Therapeutics discuss on Beyond Biotech?

Alterna CMO Dr. Narissa Kreyer explains how the company's engineered tRNA therapy AP-003 targets nonsense mutations — a shared error class causing roughly 10% of all genetic disease diagnoses — rather than individual genes, enabling a single molecule to potentially treat dozens of rare diseases simultaneously via basket trial design. Key topics include: **Nonsense mutation universe:** Only approximately 19 nonsense mutations exist in nature, making them a contained, tractable target class. AP-003 focuses on ARG2TGA, the most prevalent of these 19 stop signals. Because these mutations are conserved across different genes and diseases, one engineered tRNA can address multiple conditions rather than requiring disease-by-disease drug development programs.; **tRNA mechanism — readthrough restoration:** AP-003 works by recognizing a premature stop codon, retrieving the correct amino acid, and inserting it into the growing protein chain to restore full-length functional protein. Preclinical animal models demonstrate not just protein restoration but downstream biomarker changes confirming that restored protein is biologically functional, not merely present..

How long is this episode of Beyond Biotech?

This episode is 30 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Beyond Biotech

Rewriting the rules of genetic medicine with tRNA therapeutics

September 11, 2026

30 min episode · 2 min read

Trna Therapeutics

Episode

30 min

Read time

2 min

Topics

Career Growth, Productivity, Health & Wellness

AI-Generated Summary

Published Sep 11, 2026

Key Takeaways

✓Nonsense mutation universe: Only approximately 19 nonsense mutations exist in nature, making them a contained, tractable target class. AP-003 focuses on ARG2TGA, the most prevalent of these 19 stop signals. Because these mutations are conserved across different genes and diseases, one engineered tRNA can address multiple conditions rather than requiring disease-by-disease drug development programs.
✓tRNA mechanism — readthrough restoration: AP-003 works by recognizing a premature stop codon, retrieving the correct amino acid, and inserting it into the growing protein chain to restore full-length functional protein. Preclinical animal models demonstrate not just protein restoration but downstream biomarker changes confirming that restored protein is biologically functional, not merely present.
✓Basket trial design for rare disease recruitment: Grouping multiple inborn errors of metabolism sharing the ARG2TGA mutation into one trial solves a core rare disease problem — insufficient patient numbers per indication. Combining seven to ten diseases with shared inclusion/exclusion criteria and overlapping efficacy endpoints compresses recruitment timelines from potentially years per disease to a single concurrent study.
✓Staged clinical pathway — healthy volunteers to PKU to basket: Alterna sequences its trials deliberately: phase one in healthy Australian volunteers generates safety and pharmacokinetic data without efficacy endpoints, followed by an adult phenylketonuria study to confirm protein generation and biomarker reduction, then a pediatric-inclusive basket trial across inborn errors of metabolism — each stage de-risking the next.
✓Chronic IV dosing as a feature, not a limitation: Unlike one-time gene therapy or gene editing, AP-003 is administered as a repeatable IV infusion, modeled on lysosomal storage disorder enzyme replacement therapy, including home nursing delivery. This allows dose modification or discontinuation if safety signals emerge — a flexibility permanently administered genetic medicines cannot offer.

What It Covers

Alterna CMO Dr. Narissa Kreyer explains how the company's engineered tRNA therapy AP-003 targets nonsense mutations — a shared error class causing roughly 10% of all genetic disease diagnoses — rather than individual genes, enabling a single molecule to potentially treat dozens of rare diseases simultaneously via basket trial design.

Key Questions Answered

•Nonsense mutation universe: Only approximately 19 nonsense mutations exist in nature, making them a contained, tractable target class. AP-003 focuses on ARG2TGA, the most prevalent of these 19 stop signals. Because these mutations are conserved across different genes and diseases, one engineered tRNA can address multiple conditions rather than requiring disease-by-disease drug development programs.
•tRNA mechanism — readthrough restoration: AP-003 works by recognizing a premature stop codon, retrieving the correct amino acid, and inserting it into the growing protein chain to restore full-length functional protein. Preclinical animal models demonstrate not just protein restoration but downstream biomarker changes confirming that restored protein is biologically functional, not merely present.
•Basket trial design for rare disease recruitment: Grouping multiple inborn errors of metabolism sharing the ARG2TGA mutation into one trial solves a core rare disease problem — insufficient patient numbers per indication. Combining seven to ten diseases with shared inclusion/exclusion criteria and overlapping efficacy endpoints compresses recruitment timelines from potentially years per disease to a single concurrent study.
•Staged clinical pathway — healthy volunteers to PKU to basket: Alterna sequences its trials deliberately: phase one in healthy Australian volunteers generates safety and pharmacokinetic data without efficacy endpoints, followed by an adult phenylketonuria study to confirm protein generation and biomarker reduction, then a pediatric-inclusive basket trial across inborn errors of metabolism — each stage de-risking the next.
•Chronic IV dosing as a feature, not a limitation: Unlike one-time gene therapy or gene editing, AP-003 is administered as a repeatable IV infusion, modeled on lysosomal storage disorder enzyme replacement therapy, including home nursing delivery. This allows dose modification or discontinuation if safety signals emerge — a flexibility permanently administered genetic medicines cannot offer.

Notable Moment

Kreyer reframes the entire genetic medicine development model by pointing out that fixing a shared mutation rather than a specific gene inverts conventional drug development logic — meaning one therapy could serve patients with diseases too rare to ever justify standalone clinical trials under traditional approaches.

Know someone who'd find this useful?

Episode Transcript

And welcome to Beyond Biotech, the weekly podcast from LeBiotech. I'm Dylan Kussain, and this is episode two fourteen for the podcast. Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities: gene therapy, gene editing, mRNA. Each still has to be engineered disease by disease. Alterna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic disease diagnoses, and asked whether a single engineered molecule could address it across many conditions at once. My guest today is Doctor. Narissa Kreyer, Chief Medical Officer of Alterna. Nerissa brings two decades of rare disease drug development experience, including CMO roles at Antreta Therapeutics, Deburio Therapeutics, and Avro Bio, to the task of turning that platform thesis into an actual clinical program. We'll talk translation, trial design, and what it takes to bring the first engineered tRNA therapy into the clinic. But first, a word from our friends at Inside Biotech. Hi, everyone. My name is Karish Munchigani, and I'm the cohost of Inside Biotech, the official podcast of Biotech Connection Los Angeles or BCLA. For those who may not know, BCLA is a nonprofit organization dedicated to inspiring, educating, and connecting emerging scientists, students, entrepreneurs to help grow and diversify the biotech ecosystem in Los Angeles. On Inside Biotech, we invite you to get a behind the scenes look at one of the fastest growing biotech hubs in the country. Each month, we sit down with scientists, founders, investors, and industry leaders to talk about the cutting edge science inside their companies and the personal journeys that brought them there. From breakthrough therapeutics and AI in health care to career transitions beyond academia, we explore how science, business, and storytelling intersect to shape the future of biotech and SoCal. If you're a student exploring careers in STEM, a young professional navigating the industry, or simply curious about the people driving innovation, this podcast is for you. Search inside biotech wherever you get your podcasts and give us a listen. We'd love to have you join us. Narissa, welcome to Beyond Biotech. Thank you, Dylan. Narissa, you've held CML roles at Entrada Therapeutics, Tabiria Therapeutics, Avra Bio, and you've worked across gene therapy, neuroendocrine disease, metabolic conditions. What drew you to Alterna, this platform, especially when it's so early in its clinical life? Sure, so two things. One, the science, very interesting science, and we'll get into that in much more detail today, I'm sure. The other piece is the patients. So working in rare disease throughout my career, I've had many opportunities to sit in front of patients, mothers, fathers, family members, and people are always looking for something for their child or their loved one. And as we think about rare disease drug development, Alterna …

Get the full transcript (3,948 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Beyond Biotech transcripts →